![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SETD2 |
Gene summary for SETD2 |
![]() |
Gene information | Species | Human | Gene symbol | SETD2 | Gene ID | 29072 |
Gene name | SET domain containing 2, histone lysine methyltransferase | |
Gene Alias | HBP231 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9BYW2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29072 | SETD2 | CCI_2 | Human | Cervix | CC | 1.75e-09 | 1.02e+00 | 0.5249 |
29072 | SETD2 | CCI_3 | Human | Cervix | CC | 9.30e-10 | 1.16e+00 | 0.516 |
29072 | SETD2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.73e-22 | -6.13e-01 | 0.0155 |
29072 | SETD2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.63e-02 | -4.20e-01 | -0.1808 |
29072 | SETD2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.42e-03 | -4.45e-01 | -0.1207 |
29072 | SETD2 | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.30e-03 | -8.93e-01 | -0.00410000000000005 |
29072 | SETD2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 6.11e-03 | -5.08e-01 | -0.0179 |
29072 | SETD2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.32e-03 | -4.00e-01 | 0.096 |
29072 | SETD2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.00e-04 | -4.49e-01 | 0.0338 |
29072 | SETD2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.28e-05 | -3.82e-01 | 0.0674 |
29072 | SETD2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 3.93e-05 | -5.09e-01 | 0.0588 |
29072 | SETD2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.12e-06 | -3.97e-01 | 0.294 |
29072 | SETD2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 6.45e-08 | -6.08e-01 | 0.2585 |
29072 | SETD2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.21e-13 | -5.82e-01 | 0.3005 |
29072 | SETD2 | F007 | Human | Colorectum | FAP | 1.14e-02 | -1.36e-01 | 0.1176 |
29072 | SETD2 | A001-C-207 | Human | Colorectum | FAP | 3.17e-06 | -1.97e-01 | 0.1278 |
29072 | SETD2 | A015-C-203 | Human | Colorectum | FAP | 1.96e-33 | -3.71e-01 | -0.1294 |
29072 | SETD2 | A015-C-204 | Human | Colorectum | FAP | 7.34e-08 | -1.91e-01 | -0.0228 |
29072 | SETD2 | A014-C-040 | Human | Colorectum | FAP | 3.20e-09 | -4.89e-01 | -0.1184 |
29072 | SETD2 | A002-C-201 | Human | Colorectum | FAP | 7.80e-22 | -3.39e-01 | 0.0324 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00468229 | Cervix | CC | regulation of nucleocytoplasmic transport | 31/2311 | 106/18723 | 2.68e-06 | 7.87e-05 | 31 |
GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
GO:00511689 | Cervix | CC | nuclear export | 38/2311 | 154/18723 | 1.86e-05 | 3.46e-04 | 38 |
GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:00488634 | Cervix | CC | stem cell differentiation | 46/2311 | 206/18723 | 4.11e-05 | 6.36e-04 | 46 |
GO:00512368 | Cervix | CC | establishment of RNA localization | 39/2311 | 166/18723 | 4.76e-05 | 7.25e-04 | 39 |
GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
GO:00506578 | Cervix | CC | nucleic acid transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
GO:00506588 | Cervix | CC | RNA transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
GO:00104525 | Cervix | CC | histone H3-K36 methylation | 8/2311 | 15/18723 | 1.53e-04 | 1.85e-03 | 8 |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00310 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa003101 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
hsa003102 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa003103 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa003104 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
hsa003105 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
hsa003106 | Colorectum | CRC | Lysine degradation | 18/1091 | 63/8465 | 7.21e-04 | 6.34e-03 | 4.30e-03 | 18 |
hsa003107 | Colorectum | CRC | Lysine degradation | 18/1091 | 63/8465 | 7.21e-04 | 6.34e-03 | 4.30e-03 | 18 |
hsa0031010 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa0031013 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa003108 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa0031011 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
hsa0031021 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa0031031 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa0031041 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa0031051 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa003109 | Lung | IAC | Lysine degradation | 17/1053 | 63/8465 | 1.35e-03 | 8.63e-03 | 5.73e-03 | 17 |
hsa0031012 | Lung | IAC | Lysine degradation | 17/1053 | 63/8465 | 1.35e-03 | 8.63e-03 | 5.73e-03 | 17 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SETD2 | SNV | Missense_Mutation | c.3414G>C | p.Glu1138Asp | p.E1138D | Q9BYW2 | protein_coding | tolerated_low_confidence(0.21) | benign(0.007) | TCGA-BJ-A0ZH-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SETD2 | SNV | Missense_Mutation | c.5128N>A | p.Arg1710Ser | p.R1710S | Q9BYW2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E8-A2EA-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SETD2 | SNV | Missense_Mutation | novel | c.7289G>T | p.Ser2430Ile | p.S2430I | Q9BYW2 | protein_coding | deleterious(0) | benign(0.132) | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
SETD2 | SNV | Missense_Mutation | novel | c.5998G>C | p.Asp2000His | p.D2000H | Q9BYW2 | protein_coding | tolerated(0.06) | probably_damaging(0.991) | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
SETD2 | deletion | Frame_Shift_Del | novel | c.6642delA | p.Glu2215AsnfsTer33 | p.E2215Nfs*33 | Q9BYW2 | protein_coding | TCGA-ET-A3BV-01 | Thyroid | thyroid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
SETD2 | insertion | Frame_Shift_Ins | novel | c.7290_7291insTCTACAC | p.Leu2431SerfsTer4 | p.L2431Sfs*4 | Q9BYW2 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
SETD2 | insertion | In_Frame_Ins | novel | c.5998_5999insTTATAA | p.Asp2000delinsValIleAsn | p.D2000delinsVIN | Q9BYW2 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD | ||
SETD2 | insertion | Frame_Shift_Ins | novel | c.3369_3370insCTATCTG | p.Ala1124LeufsTer8 | p.A1124Lfs*8 | Q9BYW2 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | Cyclic octapeptide derivative 1 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | 2,2-dimethylbenzopyran derivative 1 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | HIF-1alpha | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | PMID26882240-Compound-32 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | PX-478 | PX-478 | ||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | Pyrrolidine carboxamide derivative 1 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | PMID26882240-Compound-2 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | 2,2-dimethylbenzopyran derivative 2 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | Imidazo [1,2-a]pyridine compound 1 | |||
29072 | SETD2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE | PMID26882240-Compound-14 |
Page: 1 2 3 4 |